Medical Marijuana, Inc. Investment Company AXIM® Biotechnologies Files New U.S. Patent Application for Water-Soluble Cannabinoid Molecules
SAN DIEGO, May 5, 2020 /PRNewswire/ — Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that its investment company AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech” or “AXIM”) has filed an application with the United States Patent and Trademark Office (USPTO) for a patent on water-soluble cannabinoid molecules.
AXIM has created new molecular entities with cannabinoids as the centerpiece that are significantly higher in water solubility than naturally occurring cannabinoids. Specifically, the Company has created a super cannabidiol (CBD) molecule using a reaction pathway resulting in high yield of the product. Preliminary studies show that this super CBD molecule is expected to be at least 338 times more water-soluble than naturally occurring CBD. AXIM also found similar reaction pathways for creating multi-cannabinoid molecules, where different cannabinoids are incorporated into one chemical entity.
“We are known for innovation, pushing the limits and making history for the CBD industry,” said Dr. Stuart Titus, CEO of Medical Marijuana, Inc. “With AXIM’s new super CBD-like molecule, our family of companies is showing that we intend to keep growing that reputation.”
Through this invention, AXIM is providing a solution to several challenges that scientists currently face in the development of cannabinoid products and therapies. First, AXIM’s scientists are increasing cannabinoid solubility while maintaining the cannabinoid molecule’s active functional groups after dissolution so that the molecule acts like it otherwise would. Second, the Company’s research team has successfully increased the potency of the cannabinoids, therefore reducing the amount of cannabinoids needed for any indication and reducing dosage and toxicity.
“The market for CBD products has grown tremendously over the last few years as we can see by the $2.8 billion it generated in the U.S. in 2019,” said AXIM® Biotech CEO John W. Huemoeller II. “We hope to provide a solution to cannabinoid water solubility that will allow for the innovation of many new products through this patent application.”
To learn more about AXIM® Biotechnologies, Inc., visit http://aximbiotech.com/.
About AXIM® Biotechnologies
Founded in 2014, AXIM® Biotechnologies, Inc. (AXIM) is a world leader in the research and development of plant and laboratory-derived cannabinoid and oncological therapeutics. AXIM’s proprietary research intends to find new ways to diagnose and treat cancer as well as other conditions, such as the intense side effects of chemotherapy, through innovative pharmaceutical delivery systems, cannabinoid-based active pharmaceutical ingredients, and novel therapeutics.
Currently, Sapphire Biotech, Inc.’s diagnostic tool is being used to study the company’s enzyme biomarker to detect pancreatic cancer earlier than circulating tumor cells. Learn more here. For more information, please visit www.AXIMBiotech.com.
About Medical Marijuana, Inc.
We are a company of firsts®. Medical Marijuana, Inc. (MJNA) is a cannabis company with three distinct business units in the non-psychoactive cannabinoid space: a global portfolio of cannabinoid-based nutraceutical brands led by Kannaway® and HempMeds®; a pioneer in sourcing the highest-quality legal non-psychoactive cannabis products derived from industrial hemp; and a cannabinoid-based clinical research and botanical drug development sector led by its pharmaceutical investment companies and partners including AXIM® Biotechnologies, Inc. and Kannalife, Inc. Medical Marijuana, Inc. was named a top CBD producer by CNBC. Medical Marijuana, Inc. was also the first company to receive historic import permits for CBD products from the governments of Brazil, Mexico, Argentina, and Paraguay and is a leader in the development of international markets. The company’s flagship product Real Scientific Hemp Oil has been used in several successful clinical studies throughout Mexico and Brazil to understand its safety and efficacy.
Medical Marijuana, Inc.’s headquarters is in San Diego, California, and additional information is available at OTCMarkets.com or by visiting www.medicalmarijuanainc.com. To see Medical Marijuana, Inc.’s corporate video, click here.
Shareholders and consumers are also encouraged to buy CBD oil and other products at Medical Marijuana, Inc.’s shop.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act.
Investor Relations Contact:
P. (858) 283-4016
View original content: http://www.prnewswire.com/news-releases/medical-marijuana-inc-investment-company-axim-biotechnologies-files-new-us-patent-application-for-water-soluble-cannabinoid-molecules-301052738.html
SOURCE Medical Marijuana, Inc.